Home/Pipeline/NexP™ Obesity Treatment

NexP™ Obesity Treatment

Obesity

PreclinicalActive

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active

Company

Alteogen

About Alteogen

Alteogen's mission is to develop innovative biobetter and biosimilar pharmaceuticals through its proprietary technology platforms. The company achieved a watershed financial performance in 2025, with consolidated revenue of KRW 2.159 trillion (approx. $1.6B USD) and net profit of KRW 1.443 trillion, driven by its platform-centric business model of licensing and profit-sharing. Its strategy focuses on expanding its technology moat through R&D and securing global partnerships to commercialize its pipeline, while transitioning to a mature, shareholder-returning entity.

View full company profile

Therapeutic Areas

Oncology Metabolic Disorders Autoimmune Various (Platform-enabled)

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active
VIAL-INHBE (siRNA)	VIAL Dermatology CRO	Phase 1	Active